Esperion Therapeutics

Yahoo Finance • 8 days ago

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka’s bempedoic acid products, together with related milestone payments, subject to a cap, for total consideration of $50 millionAthyrium Fund... Full story

Yahoo Finance • 11 days ago

Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins

[Merck headquarters in Kenilworth, New Jersey, August 23, 2022.] JHVEPhoto * New phase 3 data found that Merck's oral PCSK9 inhibitor, enlicitide decanoate, led to greater lowering of low-density lipoprotein cholesterol (LDL-C) compared... Full story

Yahoo Finance • 25 days ago

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announc... Full story

Yahoo Finance • 26 days ago

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic Acid Receives Equal P... Full story

Yahoo Finance • last month

Earnings week ahead: ORCL, ADBE, LI, NIO, HPE, ZIM, KSS, and more

[Business finance report sales analysis] alexsl Despite a relatively light earnings calendar, the upcoming earnings week will offer investors a broad look across multiple sectors, from technology and EVs to retail, mining, and biotech, as... Full story

Yahoo Finance • last month

Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth

Solventum Corporation (NYSE:SOLV) is one of the cheap new stocks to buy now. On February 26, Solventum reported Q4 2025 financial results that exceeded expectations, despite a reported sales decline of 3.7% to $2 billion. This decrease was... Full story

Yahoo Finance • last month

Esperion to acquire Corstasis for cardiovascular franchise expansion

Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of Enbumyst, a bumetanide nasal spray. Enbumyst is approved by the US Food and Drug Adminis... Full story

Yahoo Finance • last month

Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements

Esperion Therapeutics Inc (NASDAQ:ESPR) is among the best NASDAQ penny stocks to buy according to analysts. On February 17, Esperion Therapeutics Inc (NASDAQ:ESPR) struck a deal with Alkem Laboratories regarding the sale of rival generic d... Full story

Yahoo Finance • last month

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Produ... Full story

Yahoo Finance • 4 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of c... Full story

Yahoo Finance • 4 months ago

Familial Hypercholesterolemia Market Intelligence Report 2025-2035 Featuring Regeneron, Amgen, Esperion, Aegerion, Novartis and Other Key Players - Precision Medicine Fuels Personalized Treatment Approaches

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Familial Hypercholesterolemia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.... Full story

Yahoo Finance • 4 months ago

Esperion a new overweight at Piper Sandler on CV franchise

[Wall Street sign with American flag in the background, symbolizing the financial heart of New York.] Piper Sandler has initiated coverage of Esperion Therapeutics (ESPR [https://seekingalpha.com/symbol/ESPR]) at overweight stating that t... Full story

Yahoo Finance • 5 months ago

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (... Full story

Yahoo Finance • 5 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and... Full story

Yahoo Finance • 5 months ago

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLET... Full story

Yahoo Finance • 5 months ago

Esperion Therapeutics Q3 2025 Earnings Preview

* Esperion Therapeutics (ESPR [https://seekingalpha.com/symbol/ESPR]) is scheduled to announce Q3 earnings results on Thursday, November 6th, before market open. * The consensus EPS Estimate is -$0.07 [https://seekingalpha.com/symbol/E... Full story

Yahoo Finance • 5 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, N... Full story

Yahoo Finance • 6 months ago

Biggest stock movers Wednesday: JOBY, IREN, and more

[Strategy stock chart financial graph analysis market exchange on growth business technology background with money diagram trade investment or digital progress candlestick finance data global success.] Lemon_tm Stock futures edged higher... Full story

Yahoo Finance • 6 months ago

Esperion Announces Pricing of Public Offering of Common Stock

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-st... Full story

Yahoo Finance • 6 months ago

Esperion launches proposed public offering of common stock

* Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) has commenced an underwritten public offering of shares of its common stock. Esperion also intends to grant the underwriters a 30-day option to purchase up to a... Full story